Journal of Clinical Oncology (JCO) APC and Open Access: What ASCO Actually Charges
JCO APC planning is simple: the standard route is free, while the optional OA upgrade does not have one clean fixed public ASCO sticker price.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Journal of Clinical Oncology publishing costs and open access options
APC is one cost. Funder mandates, institutional agreements, and access route timing all shape what you actually pay.
What shapes what you pay
- Journal of Clinical Oncology offers open access publishing. Check whether your institution has a read-and-publish agreement.
- Funder mandates (NIH, Wellcome, UKRI) may require immediate OA — verify compliance before choosing a subscription route.
- Accepted authors typically have 48-72 hours to choose their access route before proofs begin.
When OA is worth the cost
- When your funder or institution requires it — non-compliance can affect future funding.
- When your topic benefits from broad immediate access beyond institutional subscribers.
- Journal of Clinical Oncology's IF 41.9 means OA papers here have real citation upside.
Quick answer: Journal of Clinical Oncology does not charge a standard APC. JCO is a hybrid ASCO journal, so the default subscription route is free to authors, and the open-access route is optional. The part authors often miss is that ASCO does not currently expose one clean public JCO OA sticker price on the journal's public author pages, so the right planning answer is: free by default, optional OA if your funder or institution needs it. For the hub, see the Journal of Clinical Oncology journal page.
JCO APC at a glance
Item | Current position |
|---|---|
Journal model | Hybrid |
Standard publication route | $0 |
Submission fee | $0 |
Page charges | $0 |
Color charges | $0 |
Optional OA upgrade | Yes |
Public fixed JCO APC card | Not cleanly exposed on current public author pages |
NIH public-access route | Yes |
2024 impact factor | 41.9 |
CiteScore | 39.6 |
SJR | 10.163 |
Typical research acceptance band | Roughly 10% to 15% planning range |
If the real question is whether the paper is strong enough for JCO before the OA decision matters, use a Journal of Clinical Oncology submission readiness check. If the bigger risk is that the paper is not yet framed like a practice-changing oncology submission, use a Journal of Clinical Oncology desk-rejection risk check.
What ASCO currently says, and what it does not say
The current public JCO author guidance is clear on the parts authors actually need:
- JCO is a subscription journal with an optional OA route
- the standard route does not use page or color charges as the baseline model
- ASCO's public author surface does not present JCO with the kind of fixed, prominent APC card that Nature, Frontiers, or MDPI use
- the public-access workflow still matters for NIH-funded work even when authors stay on the free route
That means the honest answer to the query is not "JCO costs exactly X dollars." The honest answer is that JCO is free on the default route, and the OA upgrade exists without a clean public fixed-price card on the current author pages.
What authors actually choose between
Route | What the author should assume |
|---|---|
Standard subscription publication | Free to author |
Optional OA upgrade | Available after acceptance through the licensing and production workflow |
NIH-funded or public-access-sensitive work | Usually manageable without paying for immediate gold OA |
Institution or funder with OA mandate | Check coverage before assuming author out-of-pocket payment |
This is why JCO is unusual among elite oncology journals. The default route already avoids the most common hybrid-journal cost problem.
Metrics context behind the APC question
Metric | Current figure | Why it matters with the cost decision |
|---|---|---|
Impact Factor | 41.9 | JCO is still one of the top clinical-oncology owner journals |
CiteScore | 39.6 | Scopus-side visibility is equally strong |
SJR | 10.163 | Prestige-weighted influence stays elite |
Planning acceptance band | Roughly 10% to 15% | Venue fit matters far more than APC optimization |
Older public acceptance benchmark | 16% overall | Useful as historical context, not as a live current rate |
Desk-to-first editorial answer | Often days to a couple of weeks | The journal screens fit before the fee becomes the real issue |
The real commercial point is simple: the fee is not the main bottleneck at JCO. The manuscript has to clear a flagship clinical-oncology screen first.
Long-run impact factor trend
Year | Impact factor |
|---|---|
2017 | ~26.4 |
2018 | ~28.2 |
2019 | 32.9 |
2020 | 33.0 |
2021 | 44.5 |
2022 | 45.3 |
2023 | 42.7 |
2024 | 41.9 |
The year-over-year move is modestly negative. JCO is down from 42.7 in 2023 to 41.9 in 2024, but that still leaves it deep in the flagship clinical-oncology tier. The practical implication is that authors should read the OA question through fit, funder requirements, and audience, not through any fear that the journal has lost status.
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
How JCO compares with nearby oncology options
Journal | Cost structure | Metric profile | Practical fit |
|---|---|---|---|
Journal of Clinical Oncology | Free standard route, optional OA upgrade | IF 41.9, CiteScore 39.6 | Definitive clinical oncology evidence with practice consequence |
Hybrid with explicit APC band | Similar top-tier oncology prestige | Better if global oncology framing or Lancet family positioning fits better | |
Hybrid with explicit APC band | Lower top-line citation profile than JCO | Better when the paper fits the JAMA clinical-medicine lane | |
Hybrid with explicit OA route | Elite oncology but more ESMO-centered | Better when European oncology positioning is stronger | |
Premium hybrid APC | Higher biology prestige, narrower fit | Better when the core paper is cancer biology rather than clinical oncology |
The important difference is that JCO does not force the cost question early. At competitors, the APC is often public and material from the start. At JCO, the right first question is still: is this paper really a JCO paper?
What we see in pre-submission review work with JCO manuscripts
In our pre-submission review work, the APC question is usually downstream from three harder filters.
Practice-changing consequence is the real gate. A technically competent oncology paper still misses JCO when the editors do not see a treatment, guideline, or decision-level consequence.
The free route is only valuable if the paper belongs there. Authors sometimes focus on JCO's attractive cost structure when the manuscript is still better suited to a disease-specific oncology journal or a lower flagship tier.
Most authors should solve venue first, license second. If a paper is really strong enough for JCO, then the free route is a genuine advantage. If it is not, the APC discussion is mostly noise.
Submit if / Think twice if
Submit and treat the free route as a real advantage if:
- the manuscript is truly practice-changing or guideline-relevant clinical oncology
- the free standard route already satisfies your funder and access needs
- the corresponding institution can cover any OA requirement if immediate access becomes necessary
- the audience is clearly broader than one narrow disease subfield
Think twice if:
- you are optimizing around zero cost before confirming flagship fit
- the paper is translational or retrospective but not clearly practice-shaping
- your funder requires immediate gold OA and you do not yet know what support exists
- a disease-specific journal is the more honest home for the evidence package
Practical verdict
Journal of Clinical Oncology is one of the cleaner APC answers in oncology:
- $0 on the standard route
- optional OA, but without a clean public fixed-price JCO card on the current author surface
- a journal where editorial fit matters much more than the fee
For most authors, the correct planning move is:
- confirm the paper is strong enough for JCO
- confirm whether the free route already satisfies the funder
- only then decide whether immediate OA is worth paying for
Frequently asked questions
There is no standard APC to publish in Journal of Clinical Oncology. JCO is a hybrid journal, so the default subscription route is free to authors and the OA upgrade is optional.
ASCO's current public JCO author pages do not expose one clean fixed OA sticker price for Journal of Clinical Oncology. The publisher indicates that open-access pricing is handled during the post-acceptance production and licensing workflow rather than as a prominently listed public APC card.
Yes. On the standard subscription route, JCO does not charge a submission fee, page fee, color fee, or baseline publication fee. That is the default path for most authors.
Yes. JCO's standard route still works for NIH-funded authors through PubMed Central deposit and the journal's public-access workflow, even if the paper is not upgraded to immediate gold open access.
It is easiest to justify when the paper is already strong enough for JCO, the funder or institution requires immediate open access, or institutional support covers most of the bill.
Sources
Before you upload
Want the full picture on Journal of Clinical Oncology?
Scope, selectivity, what editors want, common rejection reasons, and submission context, all in one place.
These pages attract evaluation intent more than upload-ready intent.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
- Journal of Clinical Oncology Submission Guide: Editorial Screening Guide
- Is Journal of Clinical Oncology a Good Journal? The ASCO Flagship for Practice-Changing Oncology
- JCO Impact Factor 2026: 41.9, Q1
- JCO Acceptance Rate: What the Number Means for Authors
- Journal Of Clinical Oncology Pre Submission Checklist: 12 Items Editors Verify Before Peer Review
- How to Avoid Desk Rejection at Journal of Clinical Oncology
Supporting reads
Want the full picture on Journal of Clinical Oncology?
These pages attract evaluation intent more than upload-ready intent.